Expanding the Target Landscape by Drugging the Undruggable (R21 Clinical Trial Not Allowed)
ID: 359154Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Eligible Applicants

Others

Funding Category

Health

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/359154

Additional Information

http://grants.nih.gov/grants/guide/pa-files/PAR-25-442.html
Timeline
    Description

    The National Institutes of Health (NIH) is offering a funding opportunity titled "Expanding the Target Landscape by Drugging the Undruggable," aimed at supporting exploratory projects that target currently undruggable protein classes associated with intractable human diseases. Applicants are required to identify a relevant undruggable target class and propose innovative preclinical methods or agents to address treatment gaps, with a focus on developing strategies that cannot be tackled by existing therapeutic approaches. This initiative is crucial for advancing translational science and improving public health outcomes by fostering the development of novel treatments for conditions that currently lack effective therapies. Up to $275,000 is available for projects over a two-year period, with applications due by February 17, 2028. For further inquiries, interested parties can contact NIH Grants Information at grantsinfo@nih.gov.

    Point(s) of Contact
    grantsinfo@nih.gov
    Files
    Title
    Posted
    PAR-25-442-Full-Announcement.html
    PAR-25-442.html
    The National Institutes of Health (NIH), through this Notice of Funding Opportunity (NOFO), invites applications for the "Expanding the Target Landscape by Drugging the Undruggable" program, aimed at facilitating exploratory projects targeting currently undruggable protein classes in intractable human diseases. This funding opportunity, under the R21 Exploratory/Developmental Research Grant, encourages innovative strategies to modulate undruggable targets through the development of techniques or agents that selectively engage these targets. Grant applications must clearly identify a relevant undruggable target class and propose preclinical methods to address the gap in treatment options. Up to $275,000 is available for projects over two years, but clinical trials are not allowed. Eligibility extends to various organizations—including higher education institutions, nonprofits, and local governments—with an emphasis on early-stage investigators. Key dates for submission and review processes are outlined, with applications due by 5 PM local time. This initiative aligns with NIH’s broader mission to accelerate translational science and improve public health outcomes by developing novel treatments for currently untreatable conditions.
    Similar Opportunities
    Forecast for Expanding the Target Landscape by Drugging the Undruggable (R21 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is announcing a funding opportunity titled "Forecast for Expanding the Target Landscape by Drugging the Undruggable (R21 Clinical Trial Not Allowed)," aimed at small businesses engaged in innovative research on undruggable target classes associated with intractable human diseases. The initiative seeks applications that propose methods or agents capable of selectively modulating traditionally undruggable targets, such as intrinsically disordered proteins and RNA, through preclinical proof of concept studies. This funding is critical for advancing therapeutic strategies for diseases that are challenging to treat with conventional therapies. The estimated total program funding is $1,000,000, with three awards expected, and interested applicants should prepare for the application process, which is anticipated to open with a synopsis posted on August 15, 2025, and close on October 16, 2025. For further inquiries, potential applicants can contact Dr. Karlie Sharma at Karlie.sharma@nih.gov or by phone at 240-381-3118.
    HEAL Initiative-Early-Stage Discovery of New Pain Targets Within the Understudied Druggable Proteome (R03 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is inviting applications for the HEAL Initiative's funding opportunity titled "Early-Stage Discovery of New Pain Targets Within the Understudied Druggable Proteome (R03 Clinical Trial Not Allowed)." This initiative aims to support pilot projects that identify new druggable targets for pain by generating preliminary data on understudied proteins associated with pain management. The funding opportunity is particularly significant as it seeks to advance research in pain management and drug discovery, contributing to the broader goal of addressing the opioid addiction crisis. Eligible applicants can receive up to $100,000 for projects lasting one year, with applications due by July 16, 2026. For further inquiries, interested parties can contact NIH Grants Information at grantsinfo@nih.gov or visit the additional information link at https://grants.nih.gov/grants/guide/pa-files/PAR-24-197.html.
    Pilot Projects Investigating Understudied Proteins Associated with Rare Diseases (R03 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Pilot Projects Investigating Understudied Proteins Associated with Rare Diseases," aimed at supporting pilot projects that explore the roles of understudied proteins linked to rare diseases. The objective is to generate preliminary data and tools related to these proteins, which are associated with rare diseases affecting fewer than 200,000 individuals in the U.S., thereby facilitating innovative research that could lead to new drug targets and treatments. Eligible applicants include a wide range of institutions, including educational and nonprofit organizations, government entities, and small businesses, with funding available up to $100,000 for projects that can be completed within one year. Interested parties can find more information and apply by contacting NIH Grants Information at grantsinfo@nih.gov, with applications due by November 16, 2027.
    HEAL Initiative-Early-Stage Discovery of New Pain Targets Within the Understudied Druggable Proteome (R03 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity under the HEAL Initiative aimed at identifying new druggable targets for pain related to understudied proteins. This initiative invites pilot projects that focus on generating preliminary data on specific eligible proteins, particularly those with a PubMed score of less than 10, which are considered understudied and may lead to innovative pain treatments. The funding opportunity, which provides up to $100,000 for a one-year project, emphasizes the importance of diversity in applicant teams and requires coordination among grant recipients. Interested applicants should note that the application submission period begins on January 16, 2025, and clinical trials are not permitted under this grant. For further details, applicants can contact NIH Grants Information at grantsinfo@nih.gov or visit the official announcement at https://grants.nih.gov/grants/guide/pa-files/PAR-25-154.html.
    Preclinical Proof of Concept Studies for Rare Diseases (R21 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Preclinical Proof of Concept Studies for Rare Diseases (R21 Clinical Trial Not Allowed)" aimed at supporting preclinical efficacy studies for therapeutic agents targeting rare diseases. This initiative seeks to fund projects that demonstrate the effectiveness of proposed treatments in established rare disease models, along with necessary pharmacodynamic and pharmacokinetic studies, to facilitate further development towards Investigational New Drug (IND) applications or clinical trials. With a total funding budget of up to $1.2 million, the NIH anticipates awarding 3-5 grants, each with a maximum budget of $275,000 over a two-year project period. Interested applicants must submit letters of intent by May 1, 2024, with full applications due by May 3, 2024, and can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    Catalyze: Product Definition for Small Molecules, Biologics and Combination Products - Target Identification and Validation, and Preliminary Product/Lead Series Identification (R61/R33 Clinical Trials Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Catalyze: Product Definition for Small Molecules, Biologics, and Combination Products," aimed at supporting early-stage translational research for heart, lung, blood, and sleep disorders. This initiative employs a phased approach (R61/R33), where the R61 phase focuses on identifying and validating therapeutic candidates, while the R33 phase involves lead series identification for preclinical testing, emphasizing innovation and addressing therapeutic gaps. The total funding commitment is approximately $4.47 million per fiscal year from 2026 to 2028, with a maximum budget of $400,000 per year for each phase, and applications are due by December 23, 2027. Interested applicants can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    NIH Directors Transformative Research Awards (R01 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering the NIH Directors Transformative Research Awards, a federal grant opportunity aimed at supporting innovative and groundbreaking research that has the potential to significantly alter scientific paradigms or improve clinical approaches. This program encourages applications from individual scientists or groups proposing bold research across various disciplines relevant to the NIH mission, with no preliminary data required for submission. Approximately $8 million is available for Fiscal Year 2026, targeting around seven awards, each with a maximum project period of five years, and key deadlines include an opening date on August 3, 2025, and a submission deadline of September 4, 2025. Interested applicants can find more information and guidelines at the NIH Grants website or contact NIH Grants Information at grantsinfo@nih.gov for inquiries.
    NIH Director’s Transformative Research Awards (R01 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is set to announce the NIH Director’s Transformative Research Awards, a federal grant opportunity aimed at supporting innovative and unconventional research projects. This program encourages individual scientists or collaborative teams to propose groundbreaking research that has the potential to redefine scientific paradigms or develop transformative technologies, without the need for preliminary data or detailed experimental plans. With an estimated total funding of $8 million and the expectation of awarding seven grants, interested applicants should prepare their proposals in advance, as applications will be solicited starting June 20, 2025, with a closing date of September 3, 2025. For further inquiries, potential applicants can contact Dr. Patricia Labosky at TransformativeAwards@mail.nih.gov or by phone at 301-594-4863.
    Innovation Grants to Nurture Initial Translational Efforts (IGNITE): Neurotherapeutic Agent Characterization and In vivo Efficacy Studies (R61/R33 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Innovation Grants to Nurture Initial Translational Efforts (IGNITE): Neurotherapeutic Agent Characterization and In vivo Efficacy Studies (R61/R33 Clinical Trial Not Allowed)." This initiative aims to support the characterization and efficacy studies of neurotherapeutic agents intended for treating neurological disorders, with a focus on conducting pharmacodynamic, pharmacokinetic, and in vivo efficacy studies to demonstrate the biological activity of proposed therapeutic agents. The program emphasizes the importance of rigorous experimental design, collaboration, and the inclusion of diverse perspectives in research teams, aligning with NIH's mission to translate research discoveries into effective therapies. Interested applicants can apply for funding up to $499,000 per year for a total project duration not exceeding three years, with the application deadline set for October 20, 2027. For further inquiries, applicants may contact NIH Grants Information at grantsinfo@nih.gov or visit the additional information link at https://grants.nih.gov/grants/guide/pa-files/PAR-25-225.html.
    Alzheimer's Drug-Development Program (U01 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is inviting applications for the Alzheimer's Drug-Development Program (Funding Opportunity Number: PAR-24-223), aimed at supporting the preclinical and early-stage clinical development of innovative drug candidates for Alzheimer's disease (AD). The program focuses on funding activities such as medicinal chemistry, pharmacokinetics, and Investigational New Drug (IND)-enabling studies, with the goal of advancing viable therapies to address the significant public health challenge posed by AD. Eligible applicants include a wide range of organizations, such as higher education institutions, nonprofits, and tribal organizations, with awards reaching up to $1.5 million over a period of up to five years for early-stage projects. Interested parties should submit their applications by November 5, 2027, and can direct inquiries to NIH Grants Information at grantsinfo@nih.gov.